Prophylactic Use of Cranberries in Recurrent Bacterial Cystitis in Women
Primary Purpose
Recurrent Urinary Tract Infections in Women
Status
Unknown status
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Cysticlean
Placebo
Sponsored by
About this trial
This is an interventional treatment trial for Recurrent Urinary Tract Infections in Women
Eligibility Criteria
Inclusion Criteria:
- Negative urine culture
- At least 3 UTI's within 12 months prior to study entry
Exclusion Criteria:
- Anatomic abnormalities of the urinary tract
- Use of investigational drugs within 30 days prior to study entry
- Current use of warfarin
- Allergy or intolerance of cranberry products
- > 50 ml of residual urine (measured by US)
- Use of indwelling catheter
- uncontrolled diabetes
- creatinine > 250 mmol/l,
- Symptomatic vaginitis
- Pregnant or breastfeeding
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Placebo Comparator
Arm Label
Cysticlean arm
Placebo arm
Arm Description
Cysticlean (2 BID for 15 days)
Placebo (2 BID for 15 days)
Outcomes
Primary Outcome Measures
Effectiveness of the use of Cranberries in the prevention of the recurrent UTIs is women.
Follow up with urinary cultures will be evaluated for Cranberries affection in UTIs
Secondary Outcome Measures
Full Information
NCT ID
NCT03032003
First Posted
January 13, 2017
Last Updated
January 23, 2017
Sponsor
University of Thessaly
1. Study Identification
Unique Protocol Identification Number
NCT03032003
Brief Title
Prophylactic Use of Cranberries in Recurrent Bacterial Cystitis in Women
Official Title
Prophylactic Use of Cranberries in Recurrent Bacterial Cystitis in Women: A Randomized, Comparative, Study.
Study Type
Interventional
2. Study Status
Record Verification Date
January 2017
Overall Recruitment Status
Unknown status
Study Start Date
February 15, 2017 (Anticipated)
Primary Completion Date
March 31, 2018 (Anticipated)
Study Completion Date
May 31, 2018 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Thessaly
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
5. Study Description
Brief Summary
To investigate if oral administration of 240mg PAC of cranberries can reduce the number of episodes of acute bacterial cystitis and improve general QoL in women with recurrent bacterial cystitis. In addition, the effect on vagina and rectal flora will studied and the adverse effect profile of the drug will be reported.
Women with ≥3 symptomatic episodes of lower UTIs at the previous year will be recruited from the outpatient population who present to their family physician or specialist with symptomatic recurrent UTI. Informed consent will be obtained from all patients and they will be divided in groups according to their age. Urinary culture, vaginal and rectal swab will be taken from all the patients. Antibiotic treatment will be prescribed (using the drug of choice according to the urine culture and the treating physician choice). Subsequently, they will be randomized to receive combined antibiotic treatment with one capsule of Cysticlean 240mg PAC two times per day or antibiotic treatment with placebo. At 14th day post treatment and after a negative urinary culture patients will continue to receive per os, daily, one capsule of Cysticlean 240mg at bed time for 12 months or placebo respectively.
Study visits will occur at 3rd, 6th , 9th and 12th month treatment phase. A urine collection, vaginal swabs and rectal swab will be taken at study entry and at the month 3, 6, 9 and 12 visits.
Participants will be asked about medication usage, any side effects they may be experiencing at each study visit. If participants develop a UTI at any time during the study, they will be asked to visit the study site within 24 hours.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Recurrent Urinary Tract Infections in Women
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Participant
Allocation
Randomized
Enrollment
160 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Cysticlean arm
Arm Type
Active Comparator
Arm Description
Cysticlean (2 BID for 15 days)
Arm Title
Placebo arm
Arm Type
Placebo Comparator
Arm Description
Placebo (2 BID for 15 days)
Intervention Type
Other
Intervention Name(s)
Cysticlean
Intervention Description
2 BID for 15 days
Intervention Type
Other
Intervention Name(s)
Placebo
Intervention Description
2 BID for 15 days
Primary Outcome Measure Information:
Title
Effectiveness of the use of Cranberries in the prevention of the recurrent UTIs is women.
Description
Follow up with urinary cultures will be evaluated for Cranberries affection in UTIs
Time Frame
12 months
10. Eligibility
Sex
Female
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
85 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Negative urine culture
At least 3 UTI's within 12 months prior to study entry
Exclusion Criteria:
Anatomic abnormalities of the urinary tract
Use of investigational drugs within 30 days prior to study entry
Current use of warfarin
Allergy or intolerance of cranberry products
> 50 ml of residual urine (measured by US)
Use of indwelling catheter
uncontrolled diabetes
creatinine > 250 mmol/l,
Symptomatic vaginitis
Pregnant or breastfeeding
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Vasileios Tzortzis, Associated Professor
Email
tzorvas@otenet.gr
First Name & Middle Initial & Last Name or Official Title & Degree
Michael Samarinas, Consultant
Email
mikesamih@hotmail.com
12. IPD Sharing Statement
Learn more about this trial
Prophylactic Use of Cranberries in Recurrent Bacterial Cystitis in Women
We'll reach out to this number within 24 hrs